{"entity":{"id":"nct06868485","kind":"trial","name":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of WSD0922-FU Tablets, Dose level A in non-small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.","summary":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT06868485 by Wayshine Biopharm, Inc., with 40 participants planned, started 2025-08-18 and due to reach its primary completion in 2027-09-30. Interventions recorded: WSD0922-FU Tablets, Dose level A and WSD0922-FU Tablets, Dose level B.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06868485","url":"https://clinicaltrials.gov/study/NCT06868485"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06868485","phase":"2","setting":"A Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With First-Line Osimertinib Treatment and Harbor a C797S Mutation","sponsor":"Wayshine Biopharm, Inc.","enrolled":40,"outcomes":[]},"route":"/trials/nct06868485/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}